- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01486979
Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis
February 6, 2017 updated by: Novo Nordisk A/S
A Pharmacokinetic Randomized Study With a Parallel Group Design to Assess the Extent of Systemic Absorption of Estradiol During Treatment With a 10 µg or 25 µg Estradiol Vaginal Tablet Administered Once Daily for 2 Weeks Followed by 10 Weeks of Twice-Weekly Maintenance Therapy in Postmenopausal Women With Atrophic Vaginitis
This trial is conducted in Europe.
The aim of this trial is to to evaluate the extent of systemic absorption of estradiol during treatment with two different doses of estradiol in postmenopausal women with atrophic vaginitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Neu-Ulm, Germany, 89231
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subjects who are able to use German language in speaking and writing
- Postmenopausal women with at least 5 years after last menstruation, or bilateral oophorectomy performed two years or more prior to the time of screening
- Serum FSH (Follicle Stimulating Hormone) levels above 40 mIU/ml and estradiol below 20 pg/ml
- Maximum 5% superficial cells as assessed by evaluation of vaginal cytology
- Endometrial thickness below 4.0 mm (double layer), as measured by transvaginal ultrasound (if applicable)
- Availability of a normal mammogram within one year prior to trial start
- Good general health as assessed by the Investigator and based on medical history, and physical and laboratory examinations
Exclusion Criteria:
- Known or suspected allergy to trial product or related products
- Known, suspected or past history of breast cancer
- Known, suspected or past estrogen dependent neoplasia e.g. endometrial cancer
- Endometrial hyperplasia or endometrial polyps diagnosed during the screening period
- Abnormal genital bleeding of unknown etiology
- Previous estrogen and/ or progestin hormone replacement therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose
|
One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
|
Active Comparator: High dose
|
One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Area under the curve (AUC)
|
Secondary Outcome Measures
Outcome Measure |
---|
Average plasma concentration (C average)
|
Maximal concentration (Cmax)
|
Minimal concentration (Cmin)
|
Time of maximal concentration (tmax)
|
Incidence of adverse events
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
May 1, 2007
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
December 5, 2011
First Submitted That Met QC Criteria
December 6, 2011
First Posted (Estimate)
December 7, 2011
Study Record Updates
Last Update Posted (Estimate)
February 8, 2017
Last Update Submitted That Met QC Criteria
February 6, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vaginal Diseases
- Vaginitis
- Atrophic Vaginitis
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
Other Study ID Numbers
- VAG-1850
- 2006-005957-31 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasRecruitingMenopause Related ConditionsUnited States
-
Wake Forest University Health SciencesWithdrawnMenopause Related Conditions
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMenopause Related ConditionsRussian Federation
Clinical Trials on estradiol, 10 mcg
-
Glenmark Pharmaceuticals Ltd. IndiaCompletedVulvar and Vaginal AtrophyUnited States
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal Atrophy
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal AtrophyFrance, Finland, Sweden, Denmark, Norway, Hungary, Czech Republic
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal AtrophyUnited States, Canada
-
Amneal Pharmaceuticals, LLCCompletedAtrophic Vaginitis Due to MenopauseUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownType2 Diabetes Mellitus
-
Regenex Pharmaceutical, ChinaUnknownOral ContraceptiveChina
-
Merck KGaA, Darmstadt, GermanyTerminatedIsolated Cartilage Injury of the KneeGermany
-
Janssen Pharmaceutical K.K.Completed
-
Instituto PalaciosNovo Nordisk A/SCompleted